GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
1. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ. (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett, 19 (8): 2129-32. [PMID:19303290]
2. Giembycz MA. (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br J Pharmacol, 155 (3): 288-90. [PMID:18660832]
3. Giembycz MA, Newton R. (2011) Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol, (204): 415-46. [PMID:21695651]
4. Keshavarzian A, Mutlu E, Guzman JP, Forsyth C, Banan A. (2007) Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs, 16 (9): 1489-506. [PMID:17714033]
5. Mulhall AM, Droege CA, Ernst NE, Panos RJ, Zafar MA. (2015) Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opin Investig Drugs, 24 (12): 1597-611. [PMID:26419847]
6. Porteous DJ, Millar JK, Brandon NJ, Sawa A. (2011) DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med, 17 (12): 699-706. [PMID:22015021]
7. Salari-Sharif P, Abdollahi M. (2010) Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. Curr Pharm Des, 16 (33): 3661-7. [PMID:21128899]
8. Torphy TJ, Undem BJ. (1991) Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax, 46 (7): 512-23. [PMID:1877039]